Comparative Pharmacology
Head-to-head clinical analysis: AKOVAZ versus BACTROBAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AKOVAZ versus BACTROBAN.
AKOVAZ vs BACTROBAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Akovaz (ephedrine sulfate) is a sympathomimetic amine that directly stimulates alpha- and beta-adrenergic receptors, and indirectly by releasing norepinephrine from presynaptic terminals, leading to increased heart rate and contractility, and vasoconstriction.
Binds to isoleucyl-tRNA synthetase, inhibiting bacterial protein synthesis.
5 mg intravenously once daily.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
None Documented
None Documented
Terminal elimination half-life: 3-4 hours, prolonged in renal impairment (up to 8-12 hours in severe CKD).
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites and unchanged drug.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Category C
Category C
Topical Antibiotic
Topical Antibiotic